ArticlePloS one2026
Immobilized horseradish peroxidase hybrid biocatalysts for degradation of pharmaceuticals and other emerging micropollutants.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing detection of emerging pollutants (EPs), such as pharmaceuticals, personal care products, and pesticides, in water bodies, there is a growing research priority to develop efficient methods for their degradation. In the present study, the degradation of 21 EPs from different classes was investigated using horseradish peroxidase (HRP) covalently immobilized onto two photocatalytic supports, TiO2 and ZnO. The hybrid biocatalysts (TiO2-HRP and ZnO-HRP) were used to degrade EPs with and without the presence of a redox mediator, 1-hydroxybenzotriazole (HOBT). The results revealed that not all EPs were equally degraded by HRP enzymes, with some pollutants showing complete, partial, or no degradation. For example, full degradation was achieved for MBT (100%), meloxicam (99.5%) and caffeic acid (98.6%). In contrast, prometryn and MCPA showed only partial degradation, reaching 19.2% and 20%, respectively, and no degradation was observed for fluometuron and atenolol. The addition of the model redox mediator, HOBT, improved the degradation of some pollutants, for example, lincomycin-HCl degradation increased to 36.9%, while trimethoprim degradation improved to 21.5%. Additionally, several pollutants, including roxithromycin, cimetidine, and caffeine, exhibited significantly higher degradation rates when treated with the immobilized HRP enzyme (TiO2-HRP or ZnO-HRP) compared to free HRP. For instance, roxithromycin degradation increased from 0.5% to 58.2% with ZnO-HRP, and for cimetidine, TiO₂-HRP improved degradation from 0.3% to 60.1% without HOBT and from 9.0% to 66.7% with HOBT. Molecular docking with the catalytic heme cofactor retained further suggested that degradation trends were not explained by docking score alone, but were influenced by ligand access to the distal heme pocket, molecular planarity, and contact topology near catalytic residues. Finally, an integrated HRP enzyme and chemical oxidation remediation strategy was applied to degrade two pollutants, trimethoprim and DEET. For trimethoprim, TiO2-HRP combined with H2O2 and UV achieved approximately 30% degradation, while for DEET, both TiO2-HRP + H2O2 + UV and ZnO-HRP + H2O2 + UV resulted in around 40% degradation, thereby highlighting a novel application for these hybrid peroxidase-photocatalysts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.